Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2002

View Archived Issues

ACH-126443 demonstrates clinical anti-HBV activity

Solvay requests withdrawal of Luvox NDA

New data on omalizumab presented at ATS 2002

Novel metalloproteinase inhibitors designed at DuPont

CDK4 inhibitors with antitumor activity prepared and tested at Lilly

Eisai presents novel AMPA/kainate receptor antagonists

Inhibitors of apo B secretion and their use in lipoprotein disorders

Applied Research Systems patents JNK inhibitors

PDE7 inhibitors useful for T-cell-related conditions

Neurogen claims the preparation and use of CRF1 ligands

Safety of continuous infusions of GEM-231 and effects on serum extracellular PKA levels

Novel epothilone examined for pharmacokinetic behavior in phase I trial

Clinical data for histone deacetylase inhibitor FR-901228 presented in Orlando

Phase I EMD-72000 results presented at ASCO

CKD-602 evaluated clinically as a treatment for solid tumors

MicardisPlus approved in E.U. for hypertension

Sosei licenses KS Biomedix's TransMID product for recurrent high-grade glioma in Japan

Intralesional CpG ODN evaluated in patients with basal cell carcinoma and melanoma

CCI-779 well tolerated and active in renal cell carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...